Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.38 |
| ▸ | WNT1 | P04628 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081728 | 0.86 | ABL1 (0.62) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL4095418 | 0.77 | MAPK14 (0.69) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6732562 | 0.77 | ABL1 (0.44) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6807712 | 0.77 | ABL1 (0.54) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6731949 | 0.76 | ABL1 (0.39) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6808706 | 0.76 | ABL1 (0.45) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6732717 | 0.76 | ABL1 (0.74) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL5864520 | 0.75 | ABL1 (0.63) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL6841045 | 0.74 | ABL1 (0.61) | ABL1RAF1LYNMAPK9SRC | |
| SCHEMBL7068622 | 0.73 | SRC (0.60) | ABL1RAF1LYNMAPK9SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110755-A1 | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110755-A1 | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions | MAPKAPK2, MAP3K1, MAP3K2 | ABL1 273/4885RAF1 104/4885LYN 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.